Glenmark Pharmaceuticals Ltd. has launched an abiosimilar of Liraglutide, a popular anti-diabetic drug, for the first time in India, under the Lirafit™ brand, following approval from the Drug Controller General of India. Priced at around INR 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70%, and will be available only under prescription.
Lirafit™ is an anti-diabetic biosimilar designed to improve glycemic control in adult patients with type 2 diabetes. Clinical trials have shown its effectiveness in lowering glycemic parameters, weight reduction, and cardiovascular safety. Alok Malik, President and Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd. Remarked, “With this launch, we have now ventured into the injectable anti-diabetic market taking another significant stride in the diabetes therapy space,”
Liraglutide is a GLP-1 receptor agonist recommended for type 2 diabetes patients with co-morbidities like atherosclerotic cardiovascular disease and obesity, as per the American Diabetes Association, AACE Consensus Statement, and European Society of Cardiology treatment guidelines. Lirafit™ is set to significantly reduce the daily therapy cost by 70% to INR 100, making it more accessible to a wider range of type 2 diabetes patients in India.
